arcusbio.com (RCUS): Utang marang Ekuitas

Logo korporat perusahaan Arcus Corp (RCUS)

The total debt-to-equity ratio of Arcus Biosciences, Inc. (RCUS) demonstrates current financial leverage, where the value of 0.24 reflects this status. The environmental policy of Arcus Biosciences, Inc. (RCUS) is limited to waste disposal and energy control. Primary risks are associated with a high cash burn rate and the outcomes of clinical trials. Drug delivery requires a costly ultra-cold chain and air transport to preserve sample properties.

RCUS: Rasio Total Utang marang Ekuitas Arcus Biosciences 04.07.2022 - 30.10.2026

Rincian metrik komprehensif lan analitis Arcus Corp (RCUS)

- rega lan prakiraan konsensus rega:
Bagan rega Arcus Biosciences|RCUS - Rata-rata rega prakiraan
- data kapitalisasi bursa:
Nilai pasar Arcus Biosciences|RCUS - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Arcus Biosciences|RCUS - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku arcusbio.com|RCUS - Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Arcus Biosciences, Inc.|RCUS - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Arcus Biosciences, Inc.|RCUS - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Arcus Biosciences|RCUS - Tanggungan jangka dawa|Kewajiban jangka cendhak perusahaan Arcus Biosciences|Indikator likuiditas cepet arcusbio.com
- informasi bathi lan kelipatan valuasi:
RCUS - Bathi pungkasan
Analisis fundamental perusahaan:Arcus Biosciences, RCUS
Barang utama Arcus Biosciences, Inc.

Arcus Biosciences, Inc. (RCUS) specializes in developing innovative immunotherapy drugs for oncological diseases. By analyzing the current debt-to-equity ratio, an investor assesses the proportion of borrowed funds relative to the company's net assets. This ratio determines the degree of financial leverage and the risk of potential insolvency. For the biotechnology sector, low indebtedness is critical while awaiting the trial results of the TIGIT inhibitor. A stable balance sheet confirms business resilience with the support of Gilead Sciences.

Pesaing Arcus Biosciences, Inc. (RCUS)

Utang marang Ekuitas ImmunityBio|Utang marang Modal Immunocore Holdings IMCR|Utang marang Ekuitas Janux Pharma (JANX)|Zymeworks Biopharmaceuticals - Rasio Utang marang Ekuitas|Total Utang marang Modal TNGX (Tango Therapeutics)|IOVA - Rasio Total Utang marang Ekuitas|IMTX - Utang marang Ekuitas|Utang marang Modal Xencor Inc|Compass Bio (CMPX) - Utang marang Ekuitas|REPL (Replimune Inc.) - Utang marang Ekuitas|Utang marang Ekuitas Lyell Immunopharma|Utang marang Modal innate-pharma.com IPHA|Total Utang marang Modal PYXS|cgen.com (CGEN) - Rasio Utang marang Modal|IO Biotech Corp - Rasio Total Utang marang Ekuitas|Sutro Biopharma, Inc (STRO) - Utang marang Modal|INKT: Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi HOWL (Werewolf Therapeutics)|IMMX: Total Utang marang Modal|ALXO - Koefisien Total Utang marang Modal|Utang marang Ekuitas Cue Biopharma, Inc.|Rasio Total Utang marang Ekuitas PDS Biotechnology Corp (PDSB)|Utang marang Ekuitas Sonnet BioTherapeutics (SONN)|Rasio Total Utang marang Ekuitas MAIABiotech.com MAIA|Liminatus Pharma LLC - Rasio Total Utang marang Ekuitas|Total Utang marang Modal LAVA Therapeutics NV LVTX|NXTC - Utang marang Ekuitas|LPTX (Leap Therapeutics, Inc.) - Rasio Utang marang Ekuitas|intensitytherapeutics.com (INTS) - Utang marang Ekuitas|Utang marang Modal Sensei Biotherapeutics, Inc. (SNSE)|Rasio Total Utang marang Ekuitas TOVX|GRTS - Rasio Utang marang Modal|Rasio Total Utang marang Ekuitas KA (Kineta Bio)|Utang Agregat marang Modal NEXI|Total Utang marang Modal TSBX (Turnstone Biologics Corp.)|Rasio Kabeh Utang marang Dana Pribadi VCNX|Harpoon Therapeutics, Inc. - Total Utang marang Modal